A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT07138209 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: QLS32015
DRUG: Pomalidomide
DRUG: Selinexor
DRUG: Dexamethasone

Sponsor

Qilu Pharmaceutical Co., Ltd.